NYSE: NVST · Medical Instruments & Supplies
Envista Holdings (NVST) fair value and price range
As of 7 Nov 2026, Faircurve's model values Envista Holdings (NVST) at $26.05 a share. The stock last closed at $24.66, which puts the model's fair value 5.6% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 12 Nov 2026. Envista Holdings Corp.
The report adds the live price, the price chart, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 7 Nov 2026 moved the fair value from $27.44 to $26.05 (-5.1%). The peer group changed: most of the move.
What the model makes of itThe price of $24.66 is 5.6% below it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What's nextNext report on 4 Feb 2027. The next weekly run is on Saturday 14 Nov 2026.
What price range does the model give NVST?
The calibrated range for NVST over 63 trading days is $20.94 to $31.03. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 11,845 past valuations, refreshed 7 Nov 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $18.67 to $35.55. In 54% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 7 Nov 2026
Envista Holdings Corporation is an enterprise dedicated to the development and distribution of a comprehensive range of dental solutions. The company is classed under Healthcare, in Medical Instruments & Supplies.
Faircurve's model gave Envista Holdings Corp (NVST) a fair value of $26.05 a share on 7 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 31 Oct 2026, gave $27.44, so the fair value moved -5.1%. In the model's own words, the peer group changed: most of the move. The calibrated range over 63 trading days is $20.94 to $31.03, built from the fair value because there is no live options data for the stock. Calibrated weekly against realised prices, ranges built this way held the price 60% of the time at this horizon. The model grades the evidence behind this valuation as low.
Envista scores 69 out of 100 on the model's quality measure, a composite of six factors scored against comparable companies. Profitability scores 100, with ROIC of 19.3% against a peer median of 10.2%. Capital discipline scores 97, with net buybacks at 4.5% of market value against a peer median of 0.4%. Earnings quality scores 27, with FCF to net income at 0.36x. The model compares Envista with ICU Medical, Inc. (ICUI), Merit Medical Systems, Inc. (MMSI), DENTSPLY SIRONA Inc. (XRAY), LeMaitre Vascular, Inc. (LMAT), AptarGroup, Inc. (ATR) and Repligen Corporation (RGEN).
Written from the figures on this page for the 7 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does NVST report earnings, and how has the stock reacted?
Envista Holdings's next earnings report is scheduled for 4 Feb 2027. Companies can move their dates.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across NVST's last 8 reports, ignoring direction, was 5.8%.
How does NVST score on business quality?
Envista Holdings's overall quality score is 69 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 100 | 19.3%ROIC | 10.2% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 27 | 0.36xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 59 | 8.3%Revenue growth, trailing | 13.9% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 97 | 4.5%Net buybacks / market value | 0.4% |
| Balance sheetNet debt to EBITDA and interest coverage. | 77 | 0.50xNet debt / EBITDA | 3.51x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 49 | 3.2 ptsEBITDA margin downside volatility, 5y | 1.8 pts |
How does NVST compare with similar companies?
The companies in medical instruments & supplies closest to Envista Holdings in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| ICUI ICU Medical, Inc. | $177.30 | $192.51 | +8.6% | Fairly valued |
| MMSI Merit Medical Systems, Inc. | $86.69 | $82.83 | -4.5% | Fairly valued |
| TFX Teleflex Incorporated | $153.15 | $162.00 | +5.8% | Data under review |
| XRAY DENTSPLY SIRONA Inc. | $9.24 | $14.89 | +61.1% | Gap wider than 60% |
| LMAT LeMaitre Vascular, Inc. | $77.65 | $92.73 | +19.4% | Undervalued |
| ATR AptarGroup, Inc. | $141.72 | $136.33 | -3.8% | Fairly valued |
| AVTR Avantor, Inc. | $15.62 | $18.61 | +19.1% | Low evidence grade |
| RGEN Repligen Corporation | $166.52 | $141.32 | -15.1% | Overvalued |
What the comparable companies' multiples alone would give for NVST, the peer-implied price, is $30.61 a share on this run. The fair value weighs that against the company's own multiple.
All medical instruments & supplies stocks ranked by gap to fair value
Envista Holdings at a glance
Envista Holdings Corporation is an enterprise dedicated to the development and distribution of a comprehensive range of dental solutions.
- Market value
- $4.0B
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Revenue expected, next twelve months
- $3.0B
- Consensus revenue growth, next fiscal year
- +5.7%
- Analysts with estimates
- 9
- Beta to the US market
- 1.17
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Envista Holdings on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 31 Oct 2026 the model's fair value for NVST was $27.44. As of 7 Nov 2026 it is $26.05, a change of -5.1%. The peer group changed: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Envista Holdings's valuation
Is Envista Holdings stock undervalued or overvalued?
Faircurve's model puts NVST's fair value at $26.05 a share against a last close of $24.66, as of 7 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is NVST's fair value?
$26.05 a share as of 7 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $18.67 to $35.55.
What price range does the model give NVST?
$20.94 to $31.03 over 63 trading days. Ranges built this way held the price 60% of the time across 11,845 past valuations, refreshed 7 Nov 2026.
When does Envista Holdings report earnings next?
The next report is scheduled for 4 Feb 2027. Companies can move their dates.
How much has NVST moved on past earnings reports?
Across its last 8 reports the median two session move was 5.8%, ignoring direction. The largest was +23.0% around the report of 5 Feb 2026.
How confident is the model in this valuation?
The model's evidence grade for NVST is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on NVST
The model holds no idea open on NVST today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on NVST with their outcomes. A free account is enough.